Read this manager's filing book
Disclosed positions
Merck & Co., Inc.: source evidence dated 2026-08-08T03:59:59.999Z.
- Issuer
- PERSONALIS INC
- Ticker
- PSNL
- Class
- COM
- Reported value
- $188,202,236
- Reported amount
- 14,044,943
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0000310158-26-000210Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
| PERSONALIS INC | PSNL | COM | $188,202,236 | 14,044,943 | SH | None |
| MODERNA INC | MRNA | COM | $161,642,545 | 2,308,190 | SH | None |
| KYMERA THERAPEUTICS INC | KYMR | COM | $88,544,161 | 772,165 | SH | None |
| AKTIS ONCOLOGY INC | AKTS | COM | $30,710,162 | 952,844 | SH | None |
| EIKON THERAPEUTICS INC | EIKN | COM | $21,749,991 | 1,666,666 | SH | None |
| ENTRADA THERAPEUTICS INC | TRDA | COM | $12,804,692 | 1,739,768 | SH | None |
| SUTRO BIOPHARMA INC | STRO | COM | $9,042,053 | 272,351 | SH | None |
| ALECTOR INC | ALEC | COM | $7,126,896 | 3,545,719 | SH | None |
| EVAXION BIOTECH A/S | EVAX | SPONSORED ADS | $3,763,791 | 1,214,126 | SH | None |
| VIRIDIAN THERAPEUTICS INC | VRDN | COM | $1,716,015 | 93,414 | SH | None |
| XILIO THERAPEUTICS INC | XLO | COM | $1,015,308 | 105,982 | SH | None |
| TUHURA BIOSCIENCES INC | HURA | COM | $45,501 | 19,445 | SH | None |
| NEUPHORIA THERAPEUTICS INC | NEUP | COM | $43,818 | 10,027 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.